Tag:

Europe

Latest Headlines

Latest Headlines

Wall Street endorses Cyberonics, Sorin $3B merger to become neuromodulation, cardiac surgery player

Neuromodulation company Cyberonics and cardiovascular device player Sorin in an all-stock deal that now values the combination at $3 billion.

Ex-Merck Serono team bags €8.7M for PhI Parkinson's program

Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.

U.K. readies dementia R&D investment fund

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound dementia R&D investment fund.

Woodford loads board of new fund with 'golden triangle' vets

If anyone had doubts about exactly where Neil Woodford was going to aim the brunt of his new £200 million ($300 million) fund, details of the board that will oversee the venture will have washed away the uncertainty.

Ipsen picks up option to buy Canbex once PhIIa data rolls in

Ipsen has handed over €6 million ($6.8 million) for the option to buy British biotech Canbex Therapeutics.

UPDATED: Cellectis files for $115M IPO as CAR-T tech sizzles

PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.

Novartis makes Israel a priority, U.K. dreams up Alzheimer's R&D hub, Shire defends tax model

In this week's EuroBiotech Report, Novartis is getting deeper into the Israeli biotech scene, tasking BioLineRx with keeping tabs on local startups after realizing it was underexposed to the country. Alzheimer's Research UK thinks it will find the next dementia drug in the "golden triangle" of Cambridge, London and Oxford. And more.

Bioartificial adrenal device readies to follow bioartificial pancreas into the clinic

Startup Beta-O2 Technologies already has a bioartificial pancreas in a tiny three-person clinical trial. Now, it has preclinical data for its next device that uses the same implantable bioreactor technology with a new cell type--the βAir Bio-artificial Adrenal system.

Ferring bags PhIII assets to beef up orthopedic pipeline

Ferring Pharmaceuticals has snapped up the assets of BioSurface Engineering Technologies to add a pair of Phase III-ready orthopedic candidates to its pipeline. Both treatments are designed to improve bone repair.

Quantum Genomics sees stock soar after oversubscribed IPO

Strong interest from individuals in France has helped Quantum Genomics blast past its IPO targets. The open-price offering was almost 15 times oversubscribed as individuals flocked to the biotech to finance the advance of its blood pressure drug into clinical proof-of-concept trials.